Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Novel mechanism of attenuation of LPS-induced NF-κB activation by the heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells.

Thangjam GS, Dimitropoulou C, Joshi AD, Barabutis N, Shaw MC, Kovalenkov Y, Wallace CM, Fulton DJ, Patel V, Catravas JD.

Am J Respir Cell Mol Biol. 2014 May;50(5):942-52. doi: 10.1165/rcmb.2013-0214OC.

2.

LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung.

Barabutis N, Handa V, Dimitropoulou C, Rafikov R, Snead C, Kumar S, Joshi A, Thangjam G, Fulton D, Black SM, Patel V, Catravas JD.

Am J Physiol Lung Cell Mol Physiol. 2013 Jun 15;304(12):L883-93. doi: 10.1152/ajplung.00419.2012.

3.

Obligatory role of heat shock protein 90 in iNOS induction.

Luo S, Wang T, Qin H, Lei H, Xia Y.

Am J Physiol Cell Physiol. 2011 Jul;301(1):C227-33. doi: 10.1152/ajpcell.00493.2010.

4.

Heat shock protein 90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling.

Joshi AD, Dimitropoulou C, Thangjam G, Snead C, Feldman S, Barabutis N, Fulton D, Hou Y, Kumar S, Patel V, Gorshkov B, Verin AD, Black SM, Catravas JD.

Am J Respir Cell Mol Biol. 2014 Jan;50(1):170-9. doi: 10.1165/rcmb.2012-0496OC.

5.

17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion.

Kim MS, Kwak HJ, Lee JW, Kim HJ, Park MJ, Park JB, Choi KH, Yoo H, Shin SH, Shin WS, Song ES, Lee SH.

Mol Cancer Res. 2008 Nov;6(11):1657-65. doi: 10.1158/1541-7786.MCR-08-0034.

6.

Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ.

Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356.

7.

The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.

Higashi C, Saji C, Yamada K, Kagawa H, Ohga R, Taira T, Fujimuro M.

Biol Pharm Bull. 2012;35(5):725-30.

8.

HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.

van der Kraan AG, Chai RC, Singh PP, Lang BJ, Xu J, Gillespie MT, Price JT, Quinn JM.

Biochem J. 2013 Apr 15;451(2):235-44. doi: 10.1042/BJ20121626.

PMID:
23379601
9.

Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.

Crèvecoeur J, Merville MP, Piette J, Gloire G.

Biochem Pharmacol. 2008 Jun 1;75(11):2183-91. doi: 10.1016/j.bcp.2008.03.009.

PMID:
18455150
10.

17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.

Lee KH, Jang AH, Yoo CG.

Am J Respir Cell Mol Biol. 2015 Sep;53(3):412-21. doi: 10.1165/rcmb.2014-0186OC.

PMID:
25633180
11.
12.

Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.

Madrigal-Matute J, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J, Martín-Ventura JL.

Cardiovasc Res. 2010 May 1;86(2):330-7. doi: 10.1093/cvr/cvq046.

PMID:
20154064
13.

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K.

Blood. 2008 Sep 1;112(5):1886-93. doi: 10.1182/blood-2008-03-143644.

14.

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.

Krishnamoorthy GP, Guida T, Alfano L, Avilla E, Santoro M, Carlomagno F, Melillo RM.

J Biol Chem. 2013 Jun 14;288(24):17481-94. doi: 10.1074/jbc.M112.439422.

15.

Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.

Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A.

J Biol Chem. 2007 Sep 28;282(39):28408-18.

16.

17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ.

Blood. 2010 Jul 8;116(1):45-53. doi: 10.1182/blood-2010-01-263756.

17.

Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.

Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS.

J Pharmacol Exp Ther. 2009 Jul;330(1):276-82. doi: 10.1124/jpet.109.151860.

18.

HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.

Shimp SK 3rd, Parson CD, Regna NL, Thomas AN, Chafin CB, Reilly CM, Nichole Rylander M.

Inflamm Res. 2012 May;61(5):521-33. doi: 10.1007/s00011-012-0442-x.

PMID:
22327510
19.

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.

Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.

Regul Toxicol Pharmacol. 2012 Dec;64(3):415-24. doi: 10.1016/j.yrtph.2012.10.003.

PMID:
23069143
20.

The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.

Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL.

J Neurochem. 2006 Dec;99(5):1351-62.

Supplemental Content

Support Center